Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novocure Ltd Ord Sh (NQ: NVCR )

14.73 +0.54 (+3.81%)
Streaming Delayed Price Updated: 2:55 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Novocure Ltd Ord Sh

< Previous 1 2 3 4 5 6 7 Next >
Calling All Investors in NovoCure Limited (NVCR): New Lawsuit Lead Plaintiff Deadline Is August 18, 2023 - Contact Bronstein, Gewirtz & Grossman, LLC Today
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NovoCure Limited (NVCR) Investors
From Law Offices of Howard G. Smith
Via Business Wire
EQUITY ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages NovoCure Limited Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – NVCR
From The Rosen Law Firm, P.A.
Via Business Wire
Scott+Scott Attorneys at Law LLP Reminds Investors That a Securities Class Action Has Been Filed Against NovoCure Limited (NASDAQ: NVCR); Lead Plaintiff Deadline is August 18, 2023
From Scott+Scott Attorneys at Law LLP
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against NovoCure Limited (NVCR)
From Robbins LLP
Via Business Wire
NOVOCURE SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR
From Kahn Swick & Foti, LLC
Via Business Wire
NVCR INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that NovoCure Limited Investors with Substantial Losses Have Opportunity to Lead the NovoCure Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
NOVOCURE LIMITED (NASDAQ: NVCR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against NovoCure Limited
From Bernstein Liebhard LLP
Via GlobeNewswire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
NOVOCURE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against NovoCure Limited and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NovoCure Limited (NVCR) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Announces Investigation into NovoCure Limited (NVCR)
From Scott+Scott Attorneys at Law LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NovoCure Limited (NVCR) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of NovoCure Limited (NVCR) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Zai Lab Limited
Via GlobeNewswire
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Novocure
Via Business Wire
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
From Novocure
Via Business Wire
Novocure Reports First Quarter 2023 Financial Results
From Novocure
Via Business Wire
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Novocure
Via Business Wire
Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
From Novocure
Via Business Wire
Novocure to Report First Quarter 2023 Financial Results
From Novocure
Via Business Wire
Kristin Stafford Joins Novocure Board of Directors
From Novocure
Via Business Wire
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
From Novocure
Via Business Wire
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
From Novocure
Via Business Wire
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
From Novocure
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.